JP7812052B2 - 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 - Google Patents
縮合イミダゾール誘導体、その調製方法及びその医薬的応用Info
- Publication number
- JP7812052B2 JP7812052B2 JP2023512797A JP2023512797A JP7812052B2 JP 7812052 B2 JP7812052 B2 JP 7812052B2 JP 2023512797 A JP2023512797 A JP 2023512797A JP 2023512797 A JP2023512797 A JP 2023512797A JP 7812052 B2 JP7812052 B2 JP 7812052B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- general formula
- compound
- mixture
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025280769A JP2026053592A (ja) | 2020-09-01 | 2025-12-24 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010905693 | 2020-09-01 | ||
| CN202010905693.4 | 2020-09-01 | ||
| CN202010984336 | 2020-09-18 | ||
| CN202010984336.1 | 2020-09-18 | ||
| CN202011124085.6 | 2020-10-20 | ||
| CN202011124085 | 2020-10-20 | ||
| CN202011253077 | 2020-11-11 | ||
| CN202011253077.1 | 2020-11-11 | ||
| CN202011407911 | 2020-12-04 | ||
| CN202011407911.8 | 2020-12-04 | ||
| CN202011627733 | 2020-12-31 | ||
| CN202011627733.X | 2020-12-31 | ||
| PCT/CN2021/115915 WO2022007979A1 (zh) | 2020-09-01 | 2021-09-01 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025280769A Division JP2026053592A (ja) | 2020-09-01 | 2025-12-24 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539584A JP2023539584A (ja) | 2023-09-15 |
| JP2023539584A5 JP2023539584A5 (cg-RX-API-DMAC10.html) | 2024-06-11 |
| JP7812052B2 true JP7812052B2 (ja) | 2026-02-09 |
Family
ID=79552285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023512797A Active JP7812052B2 (ja) | 2020-09-01 | 2021-09-01 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| JP2025280769A Pending JP2026053592A (ja) | 2020-09-01 | 2025-12-24 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025280769A Pending JP2026053592A (ja) | 2020-09-01 | 2025-12-24 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
Country Status (15)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) * | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PH12022553313A1 (en) * | 2020-06-04 | 2023-04-12 | Hangzhou Sciwind Biosciences Co Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| US20240252492A1 (en) * | 2021-01-28 | 2024-08-01 | Carmot Therapeutics ,Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| US20240360109A1 (en) * | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| CN116419923B (zh) * | 2021-08-24 | 2024-09-06 | 东宝紫星(杭州)生物医药有限公司 | 咪唑并环类化合物及其应用 |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| KR20240125004A (ko) * | 2021-12-23 | 2024-08-19 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법 |
| DK4455141T3 (da) * | 2021-12-23 | 2026-04-27 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CN119730852A (zh) * | 2022-06-23 | 2025-03-28 | 西藏海思科制药有限公司 | 一种五并五元环衍生物的药物组合物及其在医药上的应用 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| JP2026501285A (ja) * | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN116102555A (zh) * | 2022-12-23 | 2023-05-12 | 华中药业股份有限公司 | 咪唑并芳杂基类衍生物及其应用 |
| KR20250139383A (ko) * | 2023-02-02 | 2025-09-23 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 시클로알켄계 화합물의 염, 결정형 및 이의 제조 방법과 응용 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2025007843A1 (zh) * | 2023-07-03 | 2025-01-09 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型前药化合物或稠环化合物 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| AU2025207498A1 (en) | 2024-01-09 | 2026-07-09 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Glp-1r agonist pharmaceutical composition and use thereof |
| TW202545936A (zh) | 2024-02-01 | 2025-12-01 | 大陸商上海森輝醫藥有限公司 | 製備苯并二氧雜環或其鹽方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
| WO2025252201A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏豪森药业集团有限公司 | 一种环烯类衍生物的制备方法 |
| WO2026017039A1 (zh) * | 2024-07-15 | 2026-01-22 | 成都地奥九泓制药厂 | Glp-1受体激动剂化合物的盐、晶型、制备方法及其药物组合物和用途 |
| WO2026092583A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases |
| WO2026092581A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata |
| WO2026092580A1 (en) | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases |
| WO2026119119A1 (zh) * | 2024-12-02 | 2026-06-11 | 江苏恒瑞医药股份有限公司 | 氧杂环丁烷衍生物或其盐的制备方法及用途 |
| WO2026158424A1 (zh) * | 2025-01-24 | 2026-07-30 | 江苏恒瑞医药股份有限公司 | Glp-1受体激动剂的医药用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012522060A (ja) | 2009-03-30 | 2012-09-20 | トランス テック ファーマ，インコーポレイテッド | 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法 |
| WO2019239319A1 (en) | 2018-06-13 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020103815A1 (en) | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA80131C2 (en) | 2002-05-28 | 2007-08-27 | Dimensional Pharm Inc | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| EA018225B1 (ru) | 2008-03-07 | 2013-06-28 | Транстек Фарма, Инк. | Соединения оксадиазоантрацена для лечения диабета |
| JP5690839B2 (ja) * | 2009-12-04 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン産生のベンゾイミダゾール阻害薬 |
| JP6736816B2 (ja) | 2014-12-08 | 2020-08-05 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピリジンカルボキサミド誘導体、それらの製造方法およびそれらの医薬用途 |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020151707A1 (zh) * | 2019-01-22 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| JP2023538408A (ja) | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒ作動薬としての化合物 |
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| JP2023546055A (ja) | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| WO2022078380A1 (en) | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| US20220348564A1 (en) | 2021-03-24 | 2022-11-03 | Eccogene (Shanghai) Co., Ltd. | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same |
| CN117177970A (zh) * | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| US20240360109A1 (en) | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
-
2021
- 2021-09-01 JP JP2023512797A patent/JP7812052B2/ja active Active
- 2021-09-01 EP EP21837580.6A patent/EP4209490B1/en active Active
- 2021-09-01 CN CN202510138614.4A patent/CN119930603A/zh active Pending
- 2021-09-01 DK DK21837580.6T patent/DK4209490T3/da active
- 2021-09-01 CN CN202180050847.9A patent/CN115884969B/zh active Active
- 2021-09-01 EP EP26153808.6A patent/EP4706757A3/en active Pending
- 2021-09-01 WO PCT/CN2021/115915 patent/WO2022007979A1/zh not_active Ceased
- 2021-09-01 CN CN202510138725.5A patent/CN119954797A/zh active Pending
- 2021-09-01 KR KR1020237009937A patent/KR20230058660A/ko active Pending
- 2021-09-01 TW TW110132457A patent/TW202220985A/zh unknown
- 2021-09-01 PL PL21837580.6T patent/PL4209490T3/pl unknown
- 2021-09-01 AU AU2021306414A patent/AU2021306414B2/en active Active
- 2021-09-01 US US18/043,508 patent/US12227499B2/en active Active
- 2021-09-01 ES ES21837580T patent/ES3066183T3/es active Active
- 2021-09-01 FI FIEP21837580.6T patent/FI4209490T3/fi active
- 2021-09-01 MX MX2023001980A patent/MX2023001980A/es unknown
- 2021-09-01 CN CN202510139459.8A patent/CN119930604A/zh active Pending
- 2021-09-01 CA CA3188891A patent/CA3188891A1/en active Pending
- 2021-09-01 PT PT218375806T patent/PT4209490T/pt unknown
- 2021-09-01 CN CN202510139492.0A patent/CN119930605A/zh active Pending
-
2024
- 2024-03-21 US US18/612,631 patent/US12473279B2/en active Active
-
2025
- 2025-01-07 US US19/012,024 patent/US20250282773A1/en active Pending
- 2025-03-26 US US19/091,638 patent/US12459937B2/en active Active
- 2025-12-24 JP JP2025280769A patent/JP2026053592A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012522060A (ja) | 2009-03-30 | 2012-09-20 | トランス テック ファーマ，インコーポレイテッド | 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法 |
| WO2019239319A1 (en) | 2018-06-13 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| WO2020103815A1 (en) | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023524493A (ja) | 2020-04-29 | 2023-06-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119930605A (zh) | 2025-05-06 |
| JP2023539584A (ja) | 2023-09-15 |
| US20250243195A1 (en) | 2025-07-31 |
| CN115884969B (zh) | 2025-01-14 |
| CN119930604A (zh) | 2025-05-06 |
| PL4209490T3 (pl) | 2026-05-25 |
| US12459937B2 (en) | 2025-11-04 |
| AU2021306414A1 (en) | 2023-05-04 |
| CN115884969A (zh) | 2023-03-31 |
| TW202220985A (zh) | 2022-06-01 |
| US20240246958A1 (en) | 2024-07-25 |
| CN119930603A (zh) | 2025-05-06 |
| ES3066183T3 (en) | 2026-05-11 |
| EP4706757A3 (en) | 2026-04-15 |
| JP2026053592A (ja) | 2026-03-25 |
| MX2023001980A (es) | 2023-02-27 |
| US12227499B2 (en) | 2025-02-18 |
| AU2021306414B2 (en) | 2026-01-29 |
| EP4209490A4 (en) | 2023-11-22 |
| PT4209490T (pt) | 2026-03-27 |
| US12473279B2 (en) | 2025-11-18 |
| CA3188891A1 (en) | 2022-01-13 |
| FI4209490T3 (fi) | 2026-03-17 |
| CN119954797A (zh) | 2025-05-09 |
| KR20230058660A (ko) | 2023-05-03 |
| EP4209490B1 (en) | 2026-01-28 |
| US20230322756A1 (en) | 2023-10-12 |
| EP4706757A2 (en) | 2026-03-11 |
| DK4209490T3 (da) | 2026-02-23 |
| US20250282773A1 (en) | 2025-09-11 |
| EP4209490A1 (en) | 2023-07-12 |
| WO2022007979A1 (zh) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12473279B2 (en) | Fused imidazole derivative, preparation method therefor, and medical use thereof | |
| JP7813970B2 (ja) | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 | |
| CN113816948B (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN115916772B (zh) | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 | |
| CN114805336B (zh) | 稠合咪唑类化合物、其制备方法及其在医药上的应用 | |
| CN113801136B (zh) | 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用 | |
| JP7720906B2 (ja) | ピロリジン化合物及びその使用 | |
| JP2023550444A (ja) | トリアジンジオン系誘導体、その調製方法及びその医薬的応用 | |
| CN114149423B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN118894846A (zh) | 一种含硒元素类化合物及其用途 | |
| HK40090843B (en) | Fused imidazole derivative, preparation method therefor, and medical use thereof | |
| HK40090843A (en) | Fused imidazole derivative, preparation method therefor, and medical use thereof | |
| CN119841812A (zh) | 四氢异喹啉类化合物、其制备方法及其在医药上的应用 | |
| WO2022268154A1 (zh) | 新型抗乙肝化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240315 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240531 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240531 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250909 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20251111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251209 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20251223 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20251223 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7812052 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |